VANCOUVER, BC, Sept. 9, 2020 /CNW/ - Sirona Biochem Corp.
(TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased
to announce it has signed an agreement with Contract Manufacturing
Organization (CMO) WuXi AppTec ("WuXi"), Shanghai, to launch large-scale production of
TFC-1067, a novel skin dark spot remover, for global
commercialization.
WuXi has spent four months developing their manufacturing
process for commercial grade TFC-1067. This process was recently
completed, resulting in a highly pure production of TFC-1067 with
the ability to scale to any quantity needed by Sirona.
Sirona anticipates the need for multi-kilogram production of
TFC-1067 through the remainder of 2020 with sustained large-scale
quantities for commercialization required in 2021. To prevent gaps
in manufacturing, and minimize risk, the compound will be produced
in multiple locations. Roowin, the current CMO in France, will remain a producer in addition
WuXi.
Given the high potency of TFC-1067, each kilogram of Sirona's
active ingredient will produce up to ten thousand consumer size
(fifty milliliters) containers of finished product.
"With our current agreement, as well as potential new global
organizations developing interest in TFC-1067 as an active
ingredient, we anticipate needing significant quantities of
product. WuXi AppTec is one of the most highly regarded CMOs in
China and have been excellent to
work with thus far", said Dr. Howard
Verrico, CEO of Sirona Biochem. "We've taken our time
choosing a manufacturer in China
to ensure we have the most qualified company for the job. We look
forward to our relationship with WuXi and are confident about
meeting further milestones near-term."
About WuXi AppTec
WuXi AppTec provides a broad portfolio of R&D and
manufacturing services that enable companies in the pharmaceutical,
biotech and medical device industries worldwide to advance
discoveries and deliver groundbreaking treatments to patients. As
an innovation-driven and customer-focused company, WuXi AppTec
helps partners improve the productivity of advancing healthcare
products through cost-effective and efficient solutions.
With industry-leading capabilities such as R&D and
manufacturing for small molecule drugs, cell and gene therapies,
and testing for medical devices, WuXi AppTec's open-access platform
is enabling more than 3,900 collaborators from over 30 countries to
improve the health of those in need – and to realize the vision
that "every drug can be made and every disease can be treated."
For more information, please visit: www.wuxiapptec.com
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is in France and is the recipient of multiple French
national scientific awards and European Union and French government
grants. For more information, please visit
www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this press release.
---------------------------------------------
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.